Status:
UNKNOWN
Prospective Study on HIV-related Hodgkin Lymphoma
Lead Sponsor:
Harlachinger Krebshilfe e.V.
Collaborating Sponsors:
Deutsche AIDS Gesellschaft e.V.
Conditions:
HIV-associated Hodgkin Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Standard therapy for HIV-related Hodgkin lymphoma (HIV-HL) has not been defined. This trial was initiated to investigate a risk adapted treatment strategy in patients (pts) with HIV-HL as established ...
Eligibility Criteria
Inclusion
- age 18 - 75 years
- proven infection with HIV 1 (Elisa and Western Blot)
- histology-proven newly diagnosed Hodgkin lymphoma
- written, informed consent.
Exclusion
- severe cardiac, hepatic or pulmonary insufficiency
- severe renal insufficiency (creatinine \> 2,0 mg/dl) not caused by lymphoma
- bone marrow failure, not caused by lymphoma or HAART (neutrophils \< 1000/µl, platelets \< 70.000/µl)
- uncontrolled infection
- uncontrolled drug addiction or psychiatric disease
- pregnancy or lactation period
- prior chemotherapy of Hodgkin lymphoma
- life expectancy \< 6 weeks
- HIV-related wasting-syndrome
- active secondary malignancy with cervix carcinoma in situ, basalioma and Kaposi's sarcoma being excepted
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT01468740
Start Date
March 1 2004
End Date
July 1 2012
Last Update
November 9 2011
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Vivantes Auguste Victoria Klinikum
Berlin, Germany, 12157
2
Ärzteforum Seestrasse
Berlin, Germany, 13347
3
Universiy of Bonn
Bonn, Germany, 53127
4
University of Cologne
Cologne, Germany, 50924